Coating of human decay accelerating factor (hDAF) onto medical devices to improve biocompatibility.
In passing blood through an artificial circulatory system, the blood is exposed to surfaces that result in activation of the complement system. The consequences of the activation of complement can be extremely serious for the patient ranging from mild discomfort to respiratory distress and even anaphylaxis. An entirely novel approach was to express recombinant GPI anchored human decay accelerating factor (hDAF) using the baculovirus system and then coat the recombinant protein onto the surfaces of these materials to reduce complement activation. Expression of hDAF in Sf9 cells was shown by ELISA, FACS analysis, and Western blot. Functional activity was tested by CH50 assay. For the coating experiments a small scale model of a cardiovascular bypass circuit constructed from COBE tubing was used. hDAF was either coated onto the circuit using adsorption or covalently linked via the photoreactive crosslinker, p-azidobenzoyl hydrazide. After coating, heparinised human blood was pumped around the circuit and samples were collected into EDTA collection tubes at different time points. Complement activation was measured using a Quidel C3a-des-arg EIA. The photolinked circuits gave a reduction in C3a production of 20-50%, compared to 10-20% seen with an absorbed hDAF circuit. Furthermore, the inhibition of complement was seen over the whole time scale of the photolinked circuit, 60-90 min, whilst in the adsorbed circuit inhibition was not seen to a significant degree after 60 min. The time scale of a standard cardiac bypass is 45-90 min, therefore, the photolinked circuit results are encouraging, as significant inhibition of complement activation is seen within this time frame.
Watkins
N J
NJ
Imutran Ltd. (A Novartis Pharma AG Company), Cambridge, UK.
Braidley
P
P
Bray
C J
CJ
Savill
C M
CM
White
D J
DJ
D000327:Adsorption; D000707:Anaphylaxis / Q000276:immunology / Q000517:prevention & control; D000818:Animals; D016367:Baculoviridae / Q000235:genetics / Q000276:immunology; D001672:Biocompatible Materials; D018958:CD55 Antigens; D002315:Cardiopulmonary Bypass; D002478:Cells, Cultured; D003167:Complement Activation / Q000187:drug effects* / Q000276:immunology; D005343:Fibrinolytic Agents / Q000494:pharmacology; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D007231:Infant, Newborn; D011994:Recombinant Proteins; D012127:Respiratory Distress Syndrome, Newborn / Q000276:immunology / Q000517:prevention & control; D018411:Spodoptera / Q000166:cytology / Q000276:immunology; D013523:Surgical Equipment
D001672:Biocompatible Materials; D018958:CD55 Antigens; D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D006493:Heparin